· CORE DISCIPLINE
GCP

Good Clinical Practice

Clinical trial conduct, subject protection, and data credibility.

What this page does not claim

Educational orientation — not a determination of regulatory applicability, compliance, validation scope, or organizational approval.

WHAT IT GOVERNS

Good Clinical Practice is the international ethical and scientific standard for designing, conducting, recording, and reporting trials that involve human subjects (ICH E6). It protects the rights, safety, and wellbeing of participants and ensures the credibility of the data a trial produces — the two goals on which every marketing application ultimately rests.

WHY IT MATTERS

Unreliable trial data can put participants at risk and sink a submission years and hundreds of millions of dollars in. Informed-consent and source-data findings are among the most common FDA and EMA inspection citations, and a serious GCP breach can invalidate a pivotal study outright. GCP is where patient protection and data credibility are won or lost.

KEY FOCUS AREAS

01

Subject protection & informed consent

IRB/IEC oversight, a properly executed and documented informed-consent process, and the ethical safeguards that keep participant welfare ahead of the science.

02

Investigator & sponsor responsibilities

Clearly delineated duties — the investigator’s conduct of the trial at site and the sponsor’s oversight, safety reporting, and quality management of the whole programme.

03

Source data & the ALCOA+ trail

Source documents and the case report form linked by an intact, contemporaneous data trail, so a monitor or inspector can reconstruct exactly what happened to each subject.

04

Risk-based monitoring & oversight

A quality-by-design, risk-based approach (ICH E6(R2/R3)) that focuses monitoring and oversight on what matters most to subject safety and data reliability.

WHAT INSPECTORS LOOK AT

  • Informed-consent process and documentation (versions, dates, re-consent)
  • Protocol deviations and how they were identified, reported, and managed
  • Source-data verification against the case report form
  • Investigational product accountability and handling

KEY REGULATORY BODIES

Derived from the 11 standards SPEQ decodes for this discipline.

RELATED DISCIPLINES

SECTORS THAT OPERATE UNDER GCP

TOPIC EXPLAINERS ACROSS THIS DISCIPLINE
19 total
Pharmacovigilance Signal Management
How a safety signal is detected, validated, assessed, and acted on — the GVP process that turns individual case reports into a change to a medicine’s benefit-risk balance.
Informed Consent & Ethics Oversight
The two structural safeguards that make a clinical trial ethical — independent ethics review before it starts, and a genuine informed-consent process for every participant — and why consent is a process, not a signature.
Sponsor Oversight of Clinical Trials
A sponsor can outsource the work of a trial to a CRO but never the responsibility for it — what real oversight looks like beyond signing a contract, and what ICH E6(R3) changed.
RBM vs RBQM: Monitoring vs Quality Management
Vendors use them as synonyms; they are not. One is how you oversee a trial, the other is the lifecycle discipline that contains it — and ICH E6(R3) put the larger one at the centre of GCP.
Quality Tolerance Limits (QTLs) & KRIs
A QTL is not a site metric and a KRI breach is not a QTL breach — the two get set at the wrong level constantly, and a QTL crossing is not automatically a protocol deviation.
SDV vs SDR: Source Data Verification & Review
SDR is not "lite SDV" — they catch different failures. 100% SDV will never find the unreported adverse event sitting in the medical record, because there is no CRF entry to compare against.
Source Data, eSource & Direct Data Capture
Source data is the information; source documents are the containers — and under direct data capture the eCRF *is* the source, which makes source-data verification conceptually impossible.
Protocol Deviations & Serious Breaches
Deviation → important deviation → serious breach looks like one escalating ladder. It is not — a serious breach is a different axis with a statutory reporting clock, and a systemic GCP failure with no protocol departure can be one.
The Trial Master File (TMF) & TMF Reference Model
The document set that lets a trial be reconstructed and its GCP compliance proven — why "the TMF was complete at the end" misses the point, and who actually stewards the Reference Model now.
ICH E6(R3): The 2025 GCP Overhaul
The restructured Good Clinical Practice guideline — Principles + Annex 1, quality-by-design, RBQM, and what changes for sponsors and sites.
Decentralized Clinical Trials
How DCT elements — remote visits, telehealth, DTP shipping and eConsent — fit the GCP quality-by-design framework.
Biosimilar Development
The abbreviated, comparability-driven development pathway for a biologic shown to be highly similar to an already-licensed reference product.
Bioequivalence and Bioavailability
The pharmacokinetic comparison used to demonstrate that a test drug product performs the same in the body as a reference product — the scientific foundation of most generic drug approvals.
Data Privacy & Protection in GxP Environments
Where GDPR meets GxP record-keeping — the retention-versus-erasure conflict, health data as a special category, and encryption that survives an audit trail.
Clinical Development Strategy
A trial that runs perfectly against the wrong question wastes years and exposes participants for nothing.
Protocol Design, Estimands & Study Design
Complexity added in the protocol multiplies across every participant at every visit — and falls on people who had no part in writing it.
Site Feasibility, Startup & Management
Sites are where the protocol meets reality — and a site activated before it is ready produces the deviations that consume the study.
Study Closeout & Results Disclosure
Disclosure obligations are legal duties with deadlines, enforced independently of how the trial went.
Postauthorisation Studies & Real-World Evidence
Real-world data were collected for another purpose — whether they can support the question is a judgement that must be made explicitly.

GCP: frequently asked questions

Reference answers on Good Clinical Practice — what it governs, what regulations define it, and what it requires.

What is Good Clinical Practice (GCP)?

GCP is the international ethical and scientific standard for designing, conducting, recording, and reporting trials that involve human subjects. It protects the rights, safety, and wellbeing of participants and ensures the credibility of the data a trial produces — the two goals on which every marketing application ultimately rests.

What standard defines GCP?

The core standard is ICH E6, Good Clinical Practice, in its current revision ICH E6(R3). It sets the responsibilities of investigators and sponsors, the requirements for informed consent and ethics-committee oversight, and — through the R2/R3 revisions — a quality-by-design, risk-based approach to trial conduct and monitoring.

What does GCP require for informed consent?

GCP requires IRB/IEC oversight and a properly executed, documented informed-consent process in which participant welfare is placed ahead of the science. The consent must be obtained before trial procedures begin, using the approved version, and re-consent is required when material new information emerges.